Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Authors
Keywords
Cost-effectiveness analysis, ICER, Advanced hepatocellular carcinoma, Sorafenib
Journal
Radiation Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-05-18
DOI
10.1186/s13014-016-0644-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
- (2015) Pengfei Zhang et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
- (2013) Calogero Cammà et al. HEPATOLOGY
- Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
- (2013) Alexis Bujold et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Radiation Therapy for Hepatocellular Carcinoma
- (2011) Mary Feng et al. SEMINARS IN RADIATION ONCOLOGY
- Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?
- (2010) R. S. Finn CLINICAL CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
- (2010) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Economic evaluation of sorafenib in unresectable hepatocellular carcinoma
- (2010) Brian I. Carr et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
- (2009) Sean F. Altekruse et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
- (2009) Martin Hoyle et al. VALUE IN HEALTH
- Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
- (2008) Timo Purmonen et al. CLINICAL THERAPEUTICS
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
- (2008) Regina V. Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review
- (2008) David J. McLernon et al. MEDICAL DECISION MAKING
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
- (2008) Franck Bonnetain et al. QUALITY OF LIFE RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started